Sreelakshmi24’s Blog

where life is all about learning

Posts Tagged ‘stem cell

Cryo-Save aligns Business and step ups Growth Opportunities across Asia Pacific region

leave a comment »

Last week Cryo-Save Group, Europe’s largest stem cell company announced its plans to scale up its investments in its 100% subsidiary Cryo-Save India and Asia Pacific region to meet the emerging demands of these two high-growth markets. Cryo-Save Group will scale up its investment to 2 million Euros in the Asia Pac region with a 2 million earmarked for the India operations in the span of 36 months. Many developing countries have realised that stem cells which are present in umbilical cord blood at birth have immense potential to speed up treatments for life-threatening illnesses, injuries and disabilities – thereby opening new vistas of business opportunities for Cryo-Save Group. Increased investments to enhance sales and marketing operations along with focus on creating innovative propositions in select areas for Asia Pac customers form a part of Cryo-Save’s new business plan.

Stem cells are the natural repair kit of the human body. In the last 18 years more than 10000 patients have been treated with cord blood stem cells transplantations in over 150 countries. Umbilical cord blood stem cells have been used over the years in an increasing number of treatments including leukemia, myelodysplastic syndrome, red cell disorders and more. Currently stem cell research is being done for more than 85 diseases.

Rob Koremans,
Group CEO, Cryo-Save said, “Our new business alignment is a reflection of the significant role India plays in the company’s growth strategy. Cryo-Save is valued for its strong leadership presence in over 38 countries, cutting edge technology and fully automated storage facility that helps us to meet our customer’s needs. We have excellent long term relationships with our customers, including doctors and Government organizations across our European geographies. We are confident that our local marketing teams comprehend the diversity of Indian customers and continue to deliver sustained value“.

Speaking about the uniqueness of the Cryo-Save lab in India, Prof. Colin McGuckin, Scientific Director, Cryo-Save India said, “Our lab in Bangalore adheres to GMP & highest international standards. I was very impressed by it and we would be looking at Bangalore lab to do some of our projects”. Armed with 20 years of experience in stem cells, Professor McGuckin is an opinion leader who has been called upon by governments and hospitals around the world. He firmly believes that the stem cells which are present in umbilical cord blood at birth have immense potential to speed up treatments for life-threatening illnesses, injuries and disabilities.

Mr.V.R.Chandramouli, Managing Director, Cryo-Save India informed, “Women in India are slowly but steadily realizing the potential of banking their umbilical cord cells. It’s heartening to see this trend is omnipresent not only in metros but in other major cities of our country. Our endeavour like always has been to bring to the table a depth of expertise and experience in the stem cell banking space and we plan to devise new marketing strategies to reach out effectively to our target audience”.

Cryo-Save India is headquartered in Bangalore with a state-of-the art, one-of-its-kind, fully automated adult stem cell storage facility. The facility at Bangalore covers 10,000 sq ft with a storage capacity of 150,000 samples, expandable to 300,000 immediately. Cryo-Save India is the first company in India to offer dual storage, more than one time retrieval and confirms to global norms. The company will be offering collections and storage of ADULT stem cells derived from cord blood. The services will be available across all metros and other cities. The cost of the service is Rs. 75,000 which includes collection, processing and storing of the stem cells. The life span of the stem cells is 21 years. The payment is a onetime payment. Options of payment include a one year and six months duration instalment
schemes respectively.

Advertisements

Written by sreelakshmi

12 March, 2009 at 9:30 pm

Creator of “mini liver” & Cryo-Save Scientific director Prof. McGuckin to visit India

with one comment

020209-1537-profcolinmc1.jpgCryo-Save India today announced that their new Scientific Director Professor Colin McGuckin, will be visiting India between February 27 and March 3, 2009. Prof. McGuckin, who made a medical breakthrough in 2005 with the creation of the world’s first “mini liver” from umbilical cord blood, will share his plans on integrating new scientific technologies which may substantially speed up treatments for life-threatening illnesses, injuries and disabilities. Cryo-Save India, who has taken the initiative to organize the Professor’s visit, believes that this will act as an impetus for people in India to accept stem cell banking as a new form of health protection for the future.

During his visit, Prof. McGuckin will engage with regulatory authorities to share information that will shape future direction and progress in cord blood banking and advances in patient treatments. He will also talk about his latest discoveries in Regenerative Medicine, including his recent creation of the world’s first artificial pancreas, which may have important implications in diabetes.

Prof McGuckin, who has recently been appointed as Scientific Director for Cryo-Save, will be travelling to Bangalore, New Delhi and Mumbai.

Armed with 20 years of experience in stem cells, Professor McGuckin is an opinion leader who has been called upon by governments and hospitals around the world. He is also President of the Novus Sanguis Consortium, which brings together leading adult stem cell researchers and clinicians from across the world to work on specific diseases of the human condition, including heart disease, stroke, diabetes and organ degeneration.

Prof. Colin McGuckin Is Cryo-Save Group’s New Scientific Director

with one comment

Cryo-Save Group, Europe’s Largest Adult Stem Cell Banking Company announced the appointment of its new Scientific Director, Professor Colin McGuckin. In his new role, Professor McGuckin will be responsible for integrating new scientific technologies and keeping Cryo-Save’s storage services at the leading edge.

Professor McGuckin has made several advancements in stem cells including the creation of a “mini liver” from the umbilical cord blood, nervous tissues and blood vessels from cord blood cells as well as “pancreatic islets” – a major producer of insulin for treating diabetes amongst others.

Armed with 20 years of experience in stem cells, Professor McGuckin is an opinion leader who has been called upon by governments and hospitals around the world. He is also President of the Novus Sanguis Consortium, which brings together leading adult stem cell researchers and clinicians from across the world to work on specific diseases of the human condition, including heart disease, stroke, diabetes and organ degeneration.

Professor McGuckin stated, “My vocation is to treat patients with umbilical cord blood and I believe Cryo-Save, with their innovative and responsible program for storing cord blood will help achieve this goal faster, for more patients on an international scale.”

Rob Koremans, CEO, Cryo-Save said, “Prof. McGuckin’s recruitment is an auxiliary step in our efforts to put Cryo-Save at the forefront of the global stem cell market place. Gaining such tremendous scientific know how will help sustain financial security and contributions to patients”.


Cryo-Save India forays into the Western region

leave a comment »

Cryo-Save India, the 100% Indian subsidiary of Cryo-Save Group, announced their foray into the western region of the country by launching a full-fledged marketing set-up in Mumbai. The new office is part of their strategic plan for India and is envisioned to further strengthen the company’s position in the Indian market. To cater to parents growing need of providing bio-insurance to their offspring, Cryo-Save India has plans for a phased launch in key centres across the country. In Maharashtra, the city of Mumbai alone has 50,000 births per year and Pune has over 20,000 births every year in the Sec (Socio-Economic classification) A & A+ category. The company’s sales office is head quartered in Mumbai and their Maharashtra plans include representation in cities like Nagpur, Aurangabad, Pune, etc.

Cryo-Save India, with its corporate office in Bangalore, was recently set up with an investment of 1.8 Million Euros. Cryo-Save Group will scale up its investment to 2 million Euros within a year of its operation of the Indian subsidiary. The group company, Europe’s largest adult stem cell storage bank, has its operations in 37 countries across three continents. Cryo-Save India brings to the table a depth of expertise and experience in stem cell banking.

Cryo-Save India will be the only company in India with its unique offering of dual-storage system and this will be available for the first time in the country. They are also the only company that does automatic processing to avoid manual intervention and contamination. The company will be offering the collection and storage of ADULT stem cells derived from cord blood. The services will be available across all metros and other cities.

V.R. Chandramouli, Managing Director, Cryo-Save India, said, “We are very keen to extend our footprint to India specifically in the Western market as we see an immense market potential for adult stem cell banking or family banking in the Maharashtra region. A world-class stem cell banking service was the need of the hour for a huge market like India and Cryo-Save India will be offering this. We believe that the launch of the Indian operations has ushered in a new chapter in the quality of stem cell banking services offered.”

For more details on Cryo-Save India please visit http://www.cryo-save.com/india/index.html

Another major source of stem cells – menstrual blood

leave a comment »

Stem cells are one of the most fascinating areas of biology today. But like many growing fields of scientific inquiry, research on stem cells raises scientific questions as quickly as it generates new discoveries.

In India, menstruation blood has been considered as dirty and polluting. There have been a lot of myths, taboos and various practices related to menstruation. In olden times, the lady would be made to sit in some corner, wear only particular clothes, use a separate set of vessels for eating and drinking, and she was not allowed to cook. Other members in the family were not to even go near her, let alone touch her!!! At the end of the period, she would ‘cleanse’ herself by taking a hair bath.

Thankfully, while in some of the homes in rural India these restrictions might still be prevalent; in urban homes these rules seem to have lost effect. However, menstrual blood is still today considered sanitary waste. Yet recent findings have revealed menstrual blood to be a rich and easily accessible source of adult stem cells.

LifeCell is the first and the largest private cord blood stem cell bank and stem cell solutions provider in India which facilitates the cryogenic preservation of umbilical cord blood stem cells at its central facility in Chennai, India. They have been doing research on menstrual blood as a source of stem cells. Here is what Dr. Ajit Kumar, Chief Scientific Officer, LifeCell International has to say:

A woman’s role in society and the family is constantly changing. She dons the role of a daughter, sister, wife, mother, an entrepreneur, a working professional, a friend and much more with élan. The master stem cell or the zygote, wherein human life begins, is created when a woman’s egg is fertilized by her partner’s sperm. Shortly thereafter, this master stem cell begins to multiply into hundreds of millions of cells, including a large number of other stem cells, as the embryo develops during the early stages of pregnancy. The less specialized stem cells give rise to more specialized cell types and the process continues throughout pregnancy leading to the formation of all the cell types within the human body such as skin, muscle, nerve, bone, etc. Following birth and throughout adult life, our bodies continue to produce stem cells that serve as a vital source for regeneration and repair throughout our lifetime.

While the concept of stem cells becomes intuitive if one considers the development of complex organisms such as humans from a single cell such as the zygote and also the constant requirements for repair and replenishment of cells, it is only within the last fifty years that stem cells have been recognized for their therapeutic value. It is these therapeutic applications that have become the primary focus of studies by researchers and scientists from around the world. Since the very first bone marrow transplant in the 1950’s, to the 1980’s and ’90’s, when more than 16,000 stem cell transplants were performed to treat leukemia and immune system diseases, research into regenerative cellular therapies for a wide range of human diseases has rapidly advanced. Most recently, medical researchers have discovered adult stem cells in the endometrial lining of the uterus.

Another path breaking discovery in this area is that menstrual blood itself is a rich source of stem cells and serves as a potential source for promising regenerative therapies to treat heart disease, diabetes, neurological disorders like spinal cord injury, Parkinson’s and Alzheimer’s diseases, in addition to cosmeceutical applications such as anti-aging therapies, to name a few. In simple terms potentially life-saving stem cells are found naturally in menstrual blood.

The Menstrual stem cell comes from the uterine lining (endometrium), which is shed as part of a woman’s menstrual period. These menstrual stem cells are unique because they have many properties and characteristics similar to both bone marrow and embryonic stem cells.

Until now, menstrual blood has been discarded as unsanitary waste. However, as recent research has shown menstrual fluid contains self-renewing stem cells that can be easily collected, processed and cryo-preserved for potential cellular therapies that may emerge in the future. They multiply rapidly and can differentiate into many other types of cells such as neural, cardiac, bone, fat, cartilage and possibly others; demonstrating great potential for cell therapy. Preliminary research suggests that in addition to possible use by the donor, these stem cells may also be used to benefit other family members who are genetically related to the donor, such as perhaps a parent, sibling or child.

More information on stem cells is available on www.lifecellinternational.com

Written by sreelakshmi

6 January, 2009 at 7:32 am

State-of-the-art, fully automated stem cell banking facility setup at Bangalore

leave a comment »

Cryo-Save Group announced the launch of its Indian operations through its 100 percent subsidiary –Cryo-Save India. Cryo-Save India offers a depth of expertise and experience in stem cell banking.

Stem cells are the natural repair kit of the human body. In the last 18 years more than 10000 patients have been treated with cord blood stem cells transplantations in over 150 countries. Umbilical cord blood stem cells have been used over the years in an increasing number of treatments including leukaemia, myelodysplastic syndrome, lymphomas, red cell disorders and more. Currently stem cell research is being done for more than 85 diseases.

Speaking on the occasion V.R. Chandramouli, Managing Director, Cryo-Save India, said, “We are very happy to launch the Indian subsidiary and offer our expertise in adult stem cell banking services in India. A world class stem cell banking service was the need of the hour for a huge market like India and Cryo-Save India will be offering this. We are very keen to extend our footprint to India and we are very excited about the immense market potential for adult stem cell banking or family banking in India. The launch of the Indian operations will mark a new chapter in the quality of stem cell banking services offered. Cryo-Save India will bring in our global expertise, best practices and our vast experience to the Indian customer.

Cryo-Save India will be the only company in India with its unique offering of dual-storage system. They are also the only company that does automatic processing to avoid manual intervention and contamination. The company will be offering the collection and storage of ADULT stem cells derived from cord blood. The services will be available across all metros and other cities.
Cryo-Save has never been, and does not intend to become, involved in the storage or expansion of embryonic stem cells.

Cryo-Save India is headquartered in Bangalore with a state-of-the art, one-of-its-kind, fully automated adult stem cell storage facility. The facility at Bangalore covers 10,000 sq ft with a storage capacity of 150,000 samples, extendable to 300,000 immediately. Cryo-Save India is a 100 percent subsidiary of Cryo-Save Group, which is Europe’s largest adult stem cell storage bank and has its operations in 37 countries over three continents.

For further details click on the following link:

http://www.cryo-save.com/india/index.html

Written by sreelakshmi

29 December, 2008 at 9:42 pm